UroGen Pharma (URGN) Net Cash Flow (2017 - 2026)
UroGen Pharma's (URGN) quarterly Net Cash Flow came in at -$800000.0 in Q1 2026, up 98.82% YoY from -$402368.5 in Q1 2025, and down 103.86% on a QoQ basis from $20.7 million in Q4 2025.
UroGen Pharma (URGN) Net Cash Flow (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Net Cash Flow data on file, last reported at -$800000.0 in Q1 2026.
- Quarterly Net Cash Flow rose 98.82% year-over-year to -$800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (up 122.78% YoY) and the FY2025 annual result came in at -$61.0 million, down 178.93% from the prior year.
- Net Cash Flow slipped to -$800000.0 in Q1 2026, from $20.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $99.2 million in Q3 2023 to a low of -$94.8 million in Q3 2024.
- A 5-year average of $3.9 million and a median of -$2.6 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 551.35% — and 2024, when it soared 639.49%.
- Tracing URGN's Net Cash Flow over 5 years: stood at $26.7 million in 2022, then plunged by 190.93% to -$24.3 million in 2023, then surged by 293.72% to $47.1 million in 2024, then slumped by 56.01% to $20.7 million in 2025, then tumbled by 103.86% to -$800000.0 in 2026.
- The last three Net Cash Flow figures came in at -$800000.0 (Q1 2026), $20.7 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -30.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.83 Mn |
| Jun 30, 2026 | -30.83 Mn |
| Mar 31, 2026 | -800,000.00 |
| Mar 31, 2026 | -800,000.00 |
| Dec 31, 2025 | 20.71 Mn |
| Dec 31, 2025 | 20.71 Mn |
| Sep 30, 2025 | -2.60 Mn |
| Sep 30, 2025 | -2.60 Mn |
| Jun 30, 2025 | -11.12 Mn |
| Jun 30, 2025 | -11.12 Mn |
| Mar 31, 2025 | -67.95 Mn |
| Mar 31, 2025 | -67.95 Mn |
| Dec 31, 2024 | 47.07 Mn |
| Dec 31, 2024 | 47.07 Mn |
| Sep 30, 2024 | -94.81 Mn |
| Sep 30, 2024 | -94.81 Mn |
| Jun 30, 2024 | 88.54 Mn |
| Jun 30, 2024 | 88.54 Mn |
| Mar 31, 2024 | 36.44 Mn |
| Mar 31, 2024 | 36.44 Mn |